[1]朱红涛,丁振江,赵媛媛.CYP2C19基因多态性与氯吡格雷抵抗的相关性研究[J].医学信息,2020,33(08):40-42.[doi:10.3969/j.issn.1006-1959.2020.08.014]
　ZHU Hong-tao,DING Zhen-jiang,ZHAO Yuan-yuan,et al.Correlation Between CYP2C19 Gene Polymorphism and Clopidogrel Resistance[J].Medical Information,2020,33(08):40-42.[doi:10.3969/j.issn.1006-1959.2020.08.014]
点击复制

CYP2C19基因多态性与氯吡格雷抵抗的相关性研究()

医学信息[ISSN:1006-1959/CN:61-1278/R]

卷:
33卷
期数:
2020年08期
页码:
40-42
栏目:
综述
出版日期:
2020-04-15

文章信息/Info

Title:
Correlation Between CYP2C19 Gene Polymorphism and Clopidogrel Resistance
文章编号:
1006-1959（2020）08-0040-03
作者:
朱红涛; 丁振江; 赵媛媛
（承德医学院附属医院心脏内科，河北 承德 067000）
Author(s):
ZHU Hong-tao; DING Zhen-jiang; ZHAO Yuan-yuan; et al
(Department of Cardiology,the Affiliated Hospital of Chengde Medical College,Chengde 067000,Hebei,China)
关键词:
氯吡格雷抵抗; CYP2C19; 基因多态性; 血小板功能测定
Keywords:
Clopidogrel resistance; CYP2C19; Gene polymorphism; Platelet function determination
分类号:
R511.5
DOI:
10.3969/j.issn.1006-1959.2020.08.014
文献标志码:
A
摘要:
氯吡格雷是急性冠脉综合征及经皮冠状动脉介入治疗术前、术后抗血小板治疗方案中最常用的药物，对于患者能否从中远期获益有非常重要的作用。然而近年来，随着氯吡格雷的应用，发现其对血小板的抑制存在明显的个体差异，导致部分患者不能从中获益，即存在氯吡格雷抵抗现象（CR）。CR受多方面因素的影响，而CYP2C19基因多态性是最重要的内部因素。因此，准确识别不同患者之间的基因多态性，认识CR，制定个体化抗血小板治疗方案，对于其预后尤为重要。本文将从氯吡格雷的作用机制及其代谢特点、CYP2C19基因多态性与氯吡格雷抵抗相关性、基因检测的临床应用等方面作一综述。
Abstract:
Clopidogrel is the most commonly used drug in acute coronary syndrome and percutaneous coronary intervention before and after antiplatelet therapy.It has a very important role in whether patients can benefit from the medium and long term.However,in recent years,with the application of clopidogrel,it has been found that there are obvious individual differences in the inhibition of platelets, resulting in some patients unable to benefit from it,that is,clopidogrel resistance(CR).CR is affected by many factors, and CYP2C19 gene polymorphism is the most important internal factor.Therefore,it is particularly important for the prognosis to accurately identify genetic polymorphisms among different patients,recognize CR,and formulate individualized antiplatelet treatment programs.This article will review the mechanism of action and metabolic characteristics of clopidogrel,the correlation between CYP2C19 gene polymorphism and clopidogrel resistance,and the clinical application of genetic testing.

参考文献/References:

[1]Komosa A,Lesiak M,Siniawski A,et al.Expert reviews Significance of antiplatelet therapy in emergency myocardial infarction treatment[J].Advances in Interventional Cardiology,2014(1):32-39.[2]Ibanez B,James S,Agewall S,et al.2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation[J].European Heart Journal,2018,39(2):119-177.[3]Brown SA,Pereira N.Pharmacogenomic Impact of CYP2C19 Variation on Clopidogrel Therapy in Precision Cardiovascular Medicine[J].J Pers Med,2018,8(1):8.[4]陈琳,郭成贤,阳国平,等.影响氯吡格雷反应个体差异的非遗传与遗传因素研究进展[J].中国临床药理学与治疗学,2015,20(10):1177-1182.[5]宋莹,袁晋青.CYP2C19基因检测在氯吡格雷治疗中的临床意义[J].中国分子心脏病学杂志,2014(4):1039-1042.[6]Bockeria OL,Kudzoeva ZF,Shvarts VA,et al.The possibility of selecting optimal antiplatelet therapy in patients with coronary heart disease in terms of CYP2C19 polymorphism[J].Terapevticheskii Arkhiv,2016,88(5):47.[7]Sangkuhl K,Klein TE,Altman RB.Clopidogrel pathway[J].Pharmacogentics and Genomics,2010,20(7):517-527．[8]Pereira NL.,Rihal CS,So DYF,et al.Clopidogrel pharmacogenetics state-of-the-art review and the TAILOR-PCI study(Article)[J].Circulation:Cardiovascular Interventions,2019,12(4)．[9]Song BL,Wan M,Tang D,et al.Effects of CYP2C19 Genetic Polymorphisms on the Pharmacokinetic and Pharmacodynamic Properties of Clopidogrel and Its Active Metabolite in Healthy Chinese Subjects[J].Clinical Therapeutics,2018,40(7):1170-1178．[10]Bergmeijer TO,Reny IL,Pakyz RE,et al.Genome-wide and candidate gene approaches of clopidogrel efficacy using pharmacodynamic and clinical end points-Rational and design of the International Clopidogrel Pharmacogenomics Consortium(ICPC)[J].American Heart Journal,2018(198):152-159．[11]Winter MP,Grove EL,DeCaterina R,et al.Advocating cardiovascular precision medicine with P2Y12 receptor inhibitors[J].Eur Heart Cardiovasa Pharmacother,2017,3(4):221．[12]Siasos G,Oikonomou E,Zaromitidou MA,et al.Clopidogrel response variability is associated with endothelial dyfunction in coronary aetery disease patients receiving dual antiplatelet therapy[J].Atherosclerosis,2015,242(1):102-108．[13]张文斌,张新霞,陈晓燕,等.P2Y12基因多态性与冠心病患者氯吡格雷抵抗的相关性研究[J].中国心血管杂志,2015,20(1):18-22．[14]Muller I,Besta F,Sehulz C,et a1.Prevalence of clopidogrel non-respenders among patients with stable angina Pectoris scheduled for elective coronary stent placement[J].Thromb Haemost,2003(89):783-787．[15]程秀丽,张飚.血小板功能检测及其临床应用[J].国际检验医学杂志,2018,39(11):1363-1367．[16]张圆,任志亮.氯吡格雷低反应性与CYP2C19基因多态性分布的研究[J].内蒙古医学杂志,2014,46(2):183-186．[17]Moon JY,Franchi F,Rollini F,et al.Role of Genetic Testing in Patients undergoing Percutaneous Coronary Intervention[J].Expert Review of Clinical Pharmacology,2017,11(5):151-164．[18]Scott SA,Sangkuhl K,Stein CM,et al.Clinical pharmacogenetics implementation consortium guidelines for CYP2C19 genotype and clopidogrel therapy:2013 update[J].Clin Pharmacol,2013,94(3):317-323．[19]姚常,黄文军,周忠国,等.CYP2C19基因多态性与氯吡格雷抵抗的关系及对冠心病PCI患者短期预后的影响[J].中国老年学杂志,2017,37(20):5039-5040．[20]You-Quan W,Dian-Gang W,Hao Y,et al.Cytochrome P450 CYP 2C19*2 Associated with Adverse 1-Year Cardiovascular Events in Patients with Acute Coronary Syndrome[J].PLoS One,2015,10(7):e0132561[21]于学会,胡樑臣,李艳华,等.氯吡格雷抵抗和CYP2C19基因多态性对急性冠脉综合征患者经皮冠状动脉介入治疗术后预后的影响[J].中国医刊,2018(2):197-201.[22]吴铮,李文铮,王长华,等.CYP2C19基因多态性与PCI术后氯吡格雷治疗患者血小板功能、炎性指标及病情转归的相关性[J].疑难病杂志,2019(8):770-774.[23]Nagashima Z,Tsukahara K,Morita S,et al.Platelet reactivity in the early and late phases of acute coronary syndromes according to cytochrome P450 2C19 phenotypes[J].Cardiol,2013,62(3):158-164.[24]Shetkar SS,Ramakrishnan S,Seth S,et al.CYP 450 2C19 polymorphisms in Indian patients with coronary artery disease[J].Indian Heart Journal,2014,66(1):16-24.[25]Jneid H.The 2012 ACCF/AHA Focused Update of the Unstable Angina/Non-ST-Elevation Myocardial Infarction(UA/NSTEMI)Guideline:A Critical Appraisal[J].Methodist Debakey Cardiovasc J,2012,8(3):26-30.

相似文献/References:

[1]曾 意,汤永红,张 平.CYP2C19基因多态性与复发性缺血性卒中关系的研究[J].医学信息,2022,35(11):22.[doi:10.3969/j.issn.1006-1959.2022.11.007]
　ZENG Yi,TANG Yong-hong,ZHANG Ping.Study on Correlation Between CYP2C19 Gene Polymorphism and Recurrent Ischemic Stroke[J].Medical Information,2022,35(08):22.[doi:10.3969/j.issn.1006-1959.2022.11.007]

更新日期/Last Update: 2020-04-15